ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
The possible renoprotective effect of denatonium benzoate in a rat model of type 2 diabetes: role of Krüppel-like factor 6 (KLF6).
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bitter taste-sensing type 2 receptors (TAS2Rs) were first discovered in the oral cavity, but their detection in extra-oral tissues like gastrointestinal tract and kidney leads to modulation of multiple (patho) physiological processes. Krüppel-like factor (KLF6) is a novel regulator of β-cell adaptation to metabolic stress and involved in multiple processes in vascular system. This research aimed to assess the possible metabolic and renal protective effect of TAS2R agonist denatonium benzoate and the antidiabetic drug sitagliptin in diabetic rats. Forty male Sprague Dawley rats were included and divided into two main groups: normal control group and fructose-fed streptozotocin-induced diabetic group. Diabetic group was subdivided into four subgroups untreated: sitagliptin, denatonium, and sitagliptin + denatonium-treated groups. All treated groups showed improvement of glycemic and lipid profiles and UACR with enhancement of renal KLF6 expression and improved histological architecture of diabetic kidney. The combination group showed the best results with most renal corpuscles returning to normal and biochemical values close to normal control. Compared to the diabetic control group, the combination group showed significantly lower fasting blood glucose, HbA1C, UACR, TGs, and LDL-C values (≈3.44, 2.1, 3.5, 1.6, and 1.5-fold reduction, respectively), and significant elevation of serum GLP, HDL-C, and renal KLF6 expression (≈2.1, 2.0, and 3.7-fold increase, respectively). Significant correlations were detected between KLF6 expression and various parameters in all rats of the experiment. This study concluded the promising role of denatonium benzoate and its combination with sitagliptin in the management of diabetes and its renal complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.